Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Primatol ; 50(3): 164-175, 2021 06.
Article in English | MEDLINE | ID: mdl-33913156

ABSTRACT

BACKGROUND: A survey was developed to characterize disease incidence, common pathology lesions, environmental characteristics, and nutrition programs within captive research marmoset colonies. METHODS: Seventeen research facilities completed the electronic survey. RESULTS: Nutritional management programs varied amongst research institutions housing marmosets; eight primary base diets were reported. The most common clinical syndromes reported were gastrointestinal disease (i.e. inflammatory bowel disease like disease, chronic lymphocytic enteritis, chronic malabsorption, chronic diarrhea), metabolic bone disease or fracture, infectious diarrhea, and oral disease (tooth root abscesses, gingivitis, tooth root resorption). The five most common pathology morphologic diagnoses were colitis, nephropathy/nephritis, enteritis, chronic lymphoplasmacytic enteritis, and cholecystitis. Obesity was more common (average 20% of a reporting institution's population) than thin body condition (average 5%). CONCLUSIONS: Through review of current practices, we aim to inspire development of evidence-based practices to standardize husbandry and nutrition practices for marmoset research colonies.


Subject(s)
Bone Diseases, Metabolic , Callithrix , Animals , Diet/veterinary , Incidence , Obesity
2.
Acad Emerg Med ; 27(6): 469-474, 2020 06.
Article in English | MEDLINE | ID: mdl-32396670

ABSTRACT

BACKGROUND: Symptom criteria for COVID-19 testing of heath care workers (HCWs) limitations on testing availability have been challenging during the COVID-19 pandemic. An evidence-based symptom criteria for identifying HCWs for testing, based on the probability of positive COVID-19 test results, would allow for a more appropriate use of testing resources. METHODS: This was an observational study of outpatient COVID-19 testing of HCWs. Prior to testing, HCWs were asked about the presence of 10 symptoms. Their responses were then compared to their subsequent pharyngeal swab COVID-19 polymerase chain reaction test results. These data were used to derive and evaluate a symptom-based testing criteria. RESULTS: A total of 961 HCWs were included in the analysis, of whom 225 (23%) had positive test results. Loss of taste or smell was the symptom with the largest positive likelihood ratio (3.33). Dry cough, regardless of the presence or absence of other symptoms, was the most sensitive (74%) and the least specific (32%) symptom. The existing testing criteria consisting of any combination of one or more of three symptoms (fever, shortness of breath, dry cough) was 93% sensitive and 9% specific (area unce the curve [AUC] = 0.63, 95% confidence interval [CI] = 0.59 to 0.67). The derived testing criteria consisting of any combination of one or more of two symptoms (fever, loss of taste or smell) was 89% sensitive and 48% specific (AUC = 0.75, 95% CI = 0.71 to 0.78). The hybrid testing criteria consisting of any combination of one or more of four symptoms (fever, shortness of breath, dry cough, loss of taste or smell) was 98% sensitive and 8% specific (AUC = 0.77, 95% CI = 0.73 to 0.80). CONCLUSION: An evidence-based approach to COVID-19 testing that at least includes fever and loss of taste or smell should be utilized when determining which HCWs should be tested.


Subject(s)
Clinical Laboratory Techniques , Coronavirus Infections/diagnosis , Health Personnel , Pneumonia, Viral/diagnosis , Ageusia/etiology , Anorexia/etiology , Betacoronavirus , COVID-19 , COVID-19 Testing , Coronavirus Infections/complications , Coronavirus Infections/physiopathology , Cough/etiology , Diarrhea/etiology , Dyspnea/etiology , Fatigue/etiology , Fever/etiology , Humans , Myalgia/etiology , Olfaction Disorders/etiology , Pandemics , Pharyngitis/etiology , Pneumonia, Viral/complications , Pneumonia, Viral/physiopathology , Polymerase Chain Reaction , SARS-CoV-2
3.
Eur J Pharmacol ; 643(2-3): 202-10, 2010 Sep 25.
Article in English | MEDLINE | ID: mdl-20621081

ABSTRACT

Microglia are commonly described as existing in resting or active states based on morphology or level of cytokine production. Extracellular ATP is a physiologically-relevant activator of microglia, which express a number of purinergic receptors. As P2Y(12) has been linked to chemotaxis, we used a panel of purinergic compounds to understand the role of ATP receptors in morphological transformation and correlate this with TNFalpha production. We quantified activation of cultured microglia with LPS or purinergic receptor agonists by using automated image analysis of cell morphology and CD11b expression and correlated this with TNFalpha release measured by ELISA. Treatment with both ATP and the P2Y(12) receptor agonist, 2-methylthio adenosine diphosphate (2MeSADP), caused a transient increase in CD11b expression (EC(50)=1.2 microM and 187 nM, respectively) and a reduction in process count that reversed within 90 min later. These changes were not accompanied by the release of TNFalpha. Forskolin, IBMX, and pertussis toxin inhibited these changes, but the PLC inhibitor, U73122, did not. 2MeSAMP blocked the ATP response, while AP4A blocked the 2MeSADP response, implicating P2Y(12/13). Microglia activation by LPS also caused an increase in CD11b expression and a reduction in process count; however, in contrast to activation by ATP, morphological transformation was accompanied by a concentration-dependent increase in TNFalpha secretion These data demonstrate that morphological transformation and TNFalpha release are separable events mediated by different, or non-convergent pathways and that although ATP can initiate morphological changes, additional factors are required to maintain activation over sustained periods.


Subject(s)
Cytokines/metabolism , Microglia/cytology , Microglia/drug effects , Purinergic Agonists/pharmacology , Purinergic Antagonists/pharmacology , Receptors, Purinergic/metabolism , Animals , CD11b Antigen/metabolism , Cells, Cultured , Enzyme Inhibitors/pharmacology , Image Processing, Computer-Assisted/methods , Microglia/metabolism , Osmolar Concentration , Purinergic P2Y Receptor Agonists/pharmacology , Purinergic P2Y Receptor Antagonists/pharmacology , Rats , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2Y12/metabolism , Time Factors , Up-Regulation/drug effects
4.
J Arthroplasty ; 23(6 Suppl 1): 110-4, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18617361

ABSTRACT

After Food and Drug Administration (FDA) approval of premixed antibiotic bone cements (polymethylmethacrylate [PMMA]), these products are being used with increasing frequency during revision and primary hip and knee arthroplasties. To date, no studies have compared the antimicrobial efficacy of more than 2 products directly. Using a 7-day modified Kirby-Bauer assay, we assessed the in vitro antibacterial properties of 5 FDA-approved, commercially available antibiotic PMMAs. Significant differences in antimicrobial activity were noted among the antibiotic PMMA products included in this investigation. Antibacterial activity of all products tested was greatest on day 1 and rapidly diminished thereafter. Results of this investigation suggest that the antibacterial efficacies of premixed antibiotic PMMA products are not equivalent.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteria/drug effects , Bone Cements , Polymethyl Methacrylate , Gentamicins/administration & dosage , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , Time Factors , Tobramycin/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...